0 results found with selected filters. Please refine the filters. Redirecting to initial search..
Table "column sort" updates the order of the bars in the chart.
downloaded on: 2025/02/17 08:24:25
Strain |
Phenotype |
Conditions |
Study |
Experiment Name |
Sex |
Age |
# of Animals |
Value |
Units |
SEM |
SD |
Method |
Method Duration |
Post Insult Time Value |
Post Insult Time Unit |
Method Notes |
Clinical Measurement Notes |
Record ID |
Study ID |
BDIX/OrlCrl |
ratio of survivors to total study population during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
77 days-163 days |
18 |
44.0 |
% |
|
|
in vivo visual assessment |
0.0 |
100 |
days |
two treatments |
5-fluorouracil + interleukin-2 |
111148 |
3196 |
BDIX/OrlCrl |
ratio of survivors to total study population during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
77 days-213 days |
21 |
9.5 |
% |
|
|
in vivo visual assessment |
0.0 |
150 |
days |
two treatments |
5-fluorouracil + thymosin alpha-1 +interleukin-2 |
111153 |
3196 |
BDIX/OrlCrl |
ratio of survivors to total study population during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
77 days-163 days |
21 |
81.0 |
% |
|
|
in vivo visual assessment |
0.0 |
100 |
days |
two treatments |
5-fluorouracil + thymosin alpha-1 +interleukin-2 |
111149 |
3196 |
BDIX/OrlCrl |
ratio of survivors to total study population during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
77 days-213 days |
18 |
0.0 |
% |
|
|
in vivo visual assessment |
0.0 |
150 |
days |
two treatments |
5-fluorouracil + interleukin-2 |
111152 |
3196 |
BDIX/OrlCrl |
ratio of survivors to total study population during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
77 days-163 days |
18 |
39.0 |
% |
|
|
in vivo visual assessment |
0.0 |
100 |
days |
two treatment |
fluorouracil 5-FU |
111147 |
3196 |
BDIX/OrlCrl |
ratio of survivors to total study population during a period of time |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
life span trait |
male |
77 days-213 days |
18 |
0.0 |
% |
|
|
in vivo visual assessment |
0.0 |
150 |
days |
two treatment |
fluorouracil 5-FU |
111151 |
3196 |
|